- Home
- MGLD vs EPIX Comparison
MGLD vs EPIX Comparison
Compare MGLD & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- EPIX
- Stock Information
- Founded
- MGLD 1996
- EPIX 2009
- Country
- MGLD United States
- EPIX Canada
- Employees
- MGLD N/A
- EPIX N/A
- Industry
- MGLD Finance/Investors Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- EPIX Health Care
- Exchange
- MGLD Nasdaq
- EPIX Nasdaq
- Market Cap
- MGLD 80.3M
- EPIX 77.2M
- IPO Year
- MGLD N/A
- EPIX N/A
- Fundamental
- Price
- MGLD $1.71
- EPIX $1.75
- Analyst Decision
- MGLD
- EPIX Hold
- Analyst Count
- MGLD 0
- EPIX 3
- Target Price
- MGLD N/A
- EPIX $2.00
- AVG Volume (30 Days)
- MGLD 24.6K
- EPIX 425.3K
- Earning Date
- MGLD 02-12-2025
- EPIX 02-11-2025
- Dividend Yield
- MGLD N/A
- EPIX N/A
- EPS Growth
- MGLD N/A
- EPIX N/A
- EPS
- MGLD N/A
- EPIX N/A
- Revenue
- MGLD $32,511,000.00
- EPIX N/A
- Revenue This Year
- MGLD N/A
- EPIX N/A
- Revenue Next Year
- MGLD N/A
- EPIX N/A
- P/E Ratio
- MGLD N/A
- EPIX N/A
- Revenue Growth
- MGLD N/A
- EPIX N/A
- 52 Week Low
- MGLD $0.78
- EPIX $1.40
- 52 Week High
- MGLD $2.10
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- MGLD 51.19
- EPIX 41.97
- Support Level
- MGLD $1.64
- EPIX $1.70
- Resistance Level
- MGLD $1.99
- EPIX $1.85
- Average True Range (ATR)
- MGLD 0.20
- EPIX 0.10
- MACD
- MGLD -0.02
- EPIX 0.03
- Stochastic Oscillator
- MGLD 23.68
- EPIX 43.66
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.